Menu
← Oncology Approval Tracker
FDA DECISION ·
Revuforj
revumenib · Syndax Pharmaceuticals
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults and children aged 1 year and older with relapsed or refractory acute leukemia bearing a KMT2A translocation.
LAMPGEN ANALYSIS
Why it matters
The menin inhibitor provides a targeted option across acute leukemia lineages that share this translocation.
What research teams should watch
Confirm the translocation rather than a nonspecific KMT2A result, and build a rapid escalation plan for differentiation syndrome.
PRIMARY RECORDS